Phenotypic characteristics of recurrence and metastasis of endometrial epithelial tumors


endometrial carcinoma
prognostic markers

How to Cite

Diakonidze, A., Beriashvili, R., & Burkadze, G. (2023). Phenotypic characteristics of recurrence and metastasis of endometrial epithelial tumors. GEORGIAN SCIENTISTS, 5(3), 165–174.


Endometrial carcinoma is a common gynecological malignancy, the incidence of which is increasing worldwide and accounts for 65,620 new cases annually. In Georgia, uterine tumors take the 3rd place in prevalence (13.3% per 100,000 women), and the 4th place in terms of mortality (4.8% per 100,000 women). Among endometrial carcinomas, endometrioid carcinomas are the most common, accounting for approximately 75-80% of endometrial malignant lesions. In recent years, there has been no significant improvement in the prognosis of endometrial carcinoma. It has also been shown that tumors that appear at an advanced stage with a high degree of malignancy and aggressive histopathological features are still common. Adjuvant therapeutic approaches today are still complex and contradictory, and there is only a small selection of treatment approaches for metastatic disease. Still, a significant difficulty is the reliable identification of the subgroup of patients who are at high risk of developing recurrence and metastases. The search for phenotypic characteristics of recurrence and metastasis of endometrial epithelial tumors is in an active phase, and there are no unambiguous data about them.


R. L. Siegel and K. D. Miller, “Cancer Statistics , 2020,” vol. 70, pp. 7–30, 2020.


R. A. Soslow et al., “Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.,” Int J Gynecol Pathol, vol. 38 Suppl 1, no. Iss 1 Suppl 1, pp. S64–S74, Jan. 2019, doi: 10.1097/PGP.0000000000000518.

M. M. Braun, E. A. Overbeek-Wager, and R. J. Grumbo, “Diagnosis and Management of Endometrial Cancer.,” Am Fam Physician, vol. 93, no. 6, pp. 468–74, Mar. 2016.

R. A. Brooks et al., “Current recommendations and recent progress in endometrial cancer.,” CA Cancer J Clin, vol. 69, no. 4, pp. 258–279, Jul. 2019, doi: 10.3322/caac.21561.

M. M. Żyła et al., “The significance of markers in the diagnosis of endometrial cancer.,” Prz Menopauzalny, vol. 15, no. 3, pp. 176–185, Nov. 2016, doi: 10.5114/pm.2016.63500.

A. A. Hashmi et al., “Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.,” Asian Pac J Cancer Prev, vol. 20, no. 9, pp. 2601–2606, Sep. 2019, doi: 10.31557/APJCP.2019.20.9.2601.

M. Köbel, B. M. Ronnett, N. Singh, R. A. Soslow, C. B. Gilks, and W. G. McCluggage, “Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.,” Int J Gynecol Pathol, vol. 38 Suppl 1, no. Iss 1 Suppl 1, pp. S123–S131, Jan. 2019, doi: 10.1097/PGP.0000000000000488.

M. M. Zyła et al., “The significance of markers in the diagnosis of endometrial cancer,” Przeglad Menopauzalny, vol. 15, no. 3. Termedia Publishing House Ltd., pp. 176–185, 2016. doi: 10.5114/pm.2016.63500.

A. C. Rodriguez, Z. Blanchard, K. A. Maurer, and J. Gertz, “Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.,” Horm Cancer, vol. 10, no. 2–3, pp. 51–63, Jun. 2019, doi: 10.1007/s12672-019-0358-9.

M. Shah, S. R. Jain, G. Oprea, and S. Shafi, “Prognostic significance of hormone receptor (ER/PR) status in endometrial carcinoma in black women: Implications with lymph node metastasis,” J. Clin. Oncol, vol. 38, May 2020.

D.-C. Ding, H.-W. Liu, Y.-H. Chang, and T.-Y. Chu, “Expression of CD133 in endometrial cancer cells and its implications.,” J Cancer, vol. 8, no. 11, pp. 2142–2153, 2017, doi: 10.7150/jca.18869.

Y. Xu, H. Zhu, D. Zhao, and J. Tan, “Endometrial stem cells: clinical application and pathological roles.,” Int J Clin Exp Med, vol. 8, no. 12, pp. 22039–44, 2015.

H. Masuda et al., “Endometrial side population cells: potential adult stem/progenitor cells in endometrium.,” Biol Reprod, vol. 93, no. 4, p. 84, Oct. 2015, doi: 10.1095/biolreprod.115.131490.

L. T. Li, G. Jiang, Q. Chen, and J. N. Zheng, “Ki67 is a promising molecular target in the diagnosis of cancer (review).,” Mol Med Rep, vol. 11, no. 3, pp. 1566–72, Mar. 2015, doi: 10.3892/mmr.2014.2914.

S. Kitson et al., “Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.,” Mod Pathol, vol. 30, no. 3, pp. 459–468, Mar. 2017, doi: 10.1038/modpathol.2016.203.

K. Horie et al., “Cyclin A is a reliable proliferation marker in endometrial cancer cell lines.,” Oncol Lett, vol. 17, no. 5, pp. 4455–4462, May 2019, doi: 10.3892/ol.2019.10135.

F. S. Ramos, L. Wons, I. J. Cavalli, and E. M. S. F. Ribeiro, “Epithelial-mesenchymal transition in cancer : An overview,” vol. 4, pp. 1–5, 2017.

O. Bilyk, M. Coatham, M. Jewer, and L.-M. Postovit, “Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology.,” Front Oncol, vol. 7, p. 145, 2017, doi: 10.3389/fonc.2017.00145.

A. Makker and M. M. Goel, “Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: An update,” Endocrine-Related Cancer, vol. 23, no. 2. BioScientifica Ltd., pp. R85–R111, Feb. 01, 2016. doi: 10.1530/ERC-15-0218.

Ł. Lewczuk, A. Pryczynicz, and K. Guzińska-Ustymowicz, “Cell adhesion molecules in endometrial cancer - A systematic review.,” Adv Med Sci, vol. 64, no. 2, pp. 423–429, Sep. 2019, doi: 10.1016/j.advms.2019.08.003.

A. Travaglino et al., “Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer.,” Am J Clin Pathol, vol. 151, no. 5, pp. 529–538, Apr. 2019, doi: 10.1093/ajcp/aqy178.

H. Gonzalez, C. Hagerling, and Z. Werb, “Roles of the immune system in cancer: from tumor initiation to metastatic progression.,” Genes Dev, vol. 32, no. 19–20, pp. 1267–1284, Oct. 2018, doi: 10.1101/gad.314617.118.

Y. Liu, “Immune response characterization of endometrial cancer.,” Oncotarget, vol. 10, no. 9, pp. 982–992, Jan. 2019, doi: 10.18632/oncotarget.26630.

M. Li, M. Li, Y. Wei, and H. Xu, “Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis.,” Front Oncol, vol. 10, p. 1202, 2020, doi: 10.3389/fonc.2020.01202.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 GEORGIAN SCIENTISTS


Download data is not yet available.


Metrics Loading ...